Oren Schaedel

MyOme, Inc. is a clinical whole genome analysis platform company that helps families understand their risk for inherited diseases. Certified under the Clinical Laboratory Improvement Amendments (CLIA), MyOme is based in San Carlos, CA. The company is a leader in polygenic modeling and leverage the power of the whole genome for a lifetime of actionable insights. In 2017, a group of geneticists, clinicians, biologists, engineers, parents, daughters, and sons formed MyOme believing that everyone can benefit from their services. MyOme maintains internet-accessible web sites, interactive user interfaces, mobile applications, and application programming interfaces for healthcare providers to complete the test requisition form (TRF) on their health system's interface. The company's proactive health report includes 78 genes identified as medically actionable by the American College of Medical Genetics and Genomics, providing a more complete picture of disease risk through clinical grade whole genome sequencing (up to 30x) and analysis. The company was founded by Matthew Rabinowitz, Kate Im, Akash Kumar, and Oren Schaedel. The CEO is Premal S. Shah.

MyOme, Inc. is a clinical whole genome analysis platform company that helps families understand their risk for inherited diseases. Certified under the Clinical Laboratory Improvement Amendments (CLIA), MyOme is based in San Carlos, CA. The company is a leader in polygenic modeling and leverage the power of the whole genome for a lifetime of actionable insights. In 2017, a group of geneticists, clinicians, biologists, engineers, parents, daughters, and sons formed MyOme believing that everyone can benefit from their services. MyOme maintains internet-accessible web sites, interactive user interfaces, mobile applications, and application programming interfaces for healthcare providers to complete the test requisition form (TRF) on their health system's interface. The company's proactive health report includes 78 genes identified as medically actionable by the American College of Medical Genetics and Genomics, providing a more complete picture of disease risk through clinical grade whole genome sequencing (up to 30x) and analysis. The company was founded by Matthew Rabinowitz, Kate Im, Akash Kumar, and Oren Schaedel. The CEO is Premal S. Shah.

MyOme, Inc. is a clinical whole genome analysis platform company that helps families understand their risk for inherited diseases. Certified under the Clinical Laboratory Improvement Amendments (CLIA), MyOme is based in San Carlos, CA. The company is a leader in polygenic modeling and leverage the power of the whole genome for a lifetime of actionable insights. In 2017, a group of geneticists, clinicians, biologists, engineers, parents, daughters, and sons formed MyOme believing that everyone can benefit from their services. MyOme maintains internet-accessible web sites, interactive user interfaces, mobile applications, and application programming interfaces for healthcare providers to complete the test requisition form (TRF) on their health system's interface. The company's proactive health report includes 78 genes identified as medically actionable by the American College of Medical Genetics and Genomics, providing a more complete picture of disease risk through clinical grade whole genome sequencing (up to 30x) and analysis. The company was founded by Matthew Rabinowitz, Kate Im, Akash Kumar, and Oren Schaedel. The CEO is Premal S. Shah.

MyOme, Inc. is a clinical whole genome analysis platform company that helps families understand their risk for inherited diseases. Certified under the Clinical Laboratory Improvement Amendments (CLIA), MyOme is based in San Carlos, CA. The company is a leader in polygenic modeling and leverage the power of the whole genome for a lifetime of actionable insights. In 2017, a group of geneticists, clinicians, biologists, engineers, parents, daughters, and sons formed MyOme believing that everyone can benefit from their services. MyOme maintains internet-accessible web sites, interactive user interfaces, mobile applications, and application programming interfaces for healthcare providers to complete the test requisition form (TRF) on their health system's interface. The company's proactive health report includes 78 genes identified as medically actionable by the American College of Medical Genetics and Genomics, providing a more complete picture of disease risk through clinical grade whole genome sequencing (up to 30x) and analysis. The company was founded by Matthew Rabinowitz, Kate Im, Akash Kumar, and Oren Schaedel. The CEO is Premal S. Shah.

MyOme, Inc. is a clinical whole genome analysis platform company that helps families understand their risk for inherited diseases. Certified under the Clinical Laboratory Improvement Amendments (CLIA), MyOme is based in San Carlos, CA. The company is a leader in polygenic modeling and leverage the power of the whole genome for a lifetime of actionable insights. In 2017, a group of geneticists, clinicians, biologists, engineers, parents, daughters, and sons formed MyOme believing that everyone can benefit from their services. MyOme maintains internet-accessible web sites, interactive user interfaces, mobile applications, and application programming interfaces for healthcare providers to complete the test requisition form (TRF) on their health system's interface. The company's proactive health report includes 78 genes identified as medically actionable by the American College of Medical Genetics and Genomics, providing a more complete picture of disease risk through clinical grade whole genome sequencing (up to 30x) and analysis. The company was founded by Matthew Rabinowitz, Kate Im, Akash Kumar, and Oren Schaedel. The CEO is Premal S. Shah.